Yuhan Corporation & Samsung Bioepis sign exclusive biosimilar sales agreement

Published: 2017-10-13 15:36:46

Updated: 2017-10-13 15:36:46

Yuhan Corporation(CEO Jung-Hee Lee) signed an exclusive sales agreement of the Remicade(generic name: infliximab) biosimilar(SB2) and the Enbrel(generic name: etanercept) biosimilar(SB4) in Korea with Samsung Bioepis(CEO Han-Seung Ko).

The Remicade biosimilar(SB2) and the Enbrel biosimilar(SB4) are antibodies developed by Samsung Bioepis through foreign and Korean clinical trials, and are TNF-...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.